Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 23.80%284.41M | 11.87%67.97M | 23.11%86.79M | 49.79%69.83M | 15.34%59.83M | 59.07%229.74M | -1.75%60.76M | 184.04%70.49M | 58.32%46.62M | 83.16%51.87M |
Net income from continuing operations | 148.08%108.61M | 92.29%21.06M | 64.84%24.1M | 208.24%42.59M | 374.94%20.87M | 704.95%43.78M | -23.64%10.95M | 128.80%14.62M | 133.85%13.82M | 120.73%4.39M |
Operating gains losses | -288.36%-53.31M | -30.18%-12.91M | -818.23%-10.28M | -357.81%-18.25M | -1,017.70%-11.88M | -55.71%-13.73M | -182.08%-9.92M | -108.77%-1.12M | 21.56%-3.99M | 306.92%1.29M |
Depreciation and amortization | 4.71%95.21M | 11.44%25.4M | 7.83%24.9M | -0.31%22.43M | -0.28%22.49M | 3.02%90.93M | 0.06%22.79M | 4.66%23.09M | 4.08%22.49M | 3.39%22.55M |
Deferred tax | 96.32%38.58M | -15.28%5.7M | 61.89%9.79M | 202.75%14.52M | 311.97%8.57M | 851.67%19.65M | 155.62%6.73M | 393.71%6.05M | -8.54%4.8M | 129.58%2.08M |
Other non cash items | 308.98%40.73M | -26.47%4.17M | 147.82%4.26M | 3,015.48%29.38M | 79.73%2.93M | 68.71%9.96M | 238.97%5.67M | 9.85%1.72M | -30.61%943K | 24.46%1.63M |
Change In working capital | -80.00%11.82M | -81.36%3.33M | -4.13%20.65M | -947.88%-24.58M | -26.13%12.42M | 285.43%59.11M | -14.89%17.85M | 317.56%21.54M | 203.24%2.9M | 137.84%16.82M |
-Change in receivables | 221.44%21.1M | 91.20%-1.12M | 198.20%17.73M | 309.13%8.2M | 44.57%-3.71M | -448.45%-17.38M | -258.86%-12.71M | 159.92%5.95M | -293.01%-3.92M | -103.90%-6.69M |
-Change in inventory | -1,723.92%-31.19M | 26.82%6M | 200.82%3.55M | 175.29%3.36M | -2,957.94%-44.1M | -111.97%-1.71M | 16.90%4.73M | -325.82%-3.52M | -184.67%-4.47M | -54.71%1.54M |
-Change in payables and accrued expense | 20.66%20.7M | 3.88%9.17M | 57.31%2.7M | -4,238.74%-43.34M | 585.43%52.18M | 1,721.02%17.15M | 232.73%8.82M | 203.19%1.72M | 83.80%-999K | 24.34%7.61M |
-Change in other current assets | -79.18%676K | -16.61%4.35M | -395.49%-4.32M | -43.51%518K | 103.01%131K | 157.81%3.25M | 389.29%5.21M | 218.00%1.46M | 153.53%917K | -403.48%-4.35M |
-Change in other current liabilities | -111.09%-366K | -1,252.13%-3.78M | -285.55%-1.73M | 171.20%2.41M | 138.03%2.74M | 39.12%3.3M | -43.55%328K | -50.11%934K | 133.33%889K | 348.70%1.15M |
-Change in other working capital | -98.34%904K | -198.43%-11.29M | -81.78%2.73M | -59.23%4.27M | -70.44%5.19M | 735.91%54.49M | 52.99%11.47M | 3,058.78%15M | 500.61%10.48M | 717.52%17.54M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 23.80%284.41M | 11.87%67.97M | 23.11%86.79M | 49.79%69.83M | 15.34%59.83M | 59.07%229.74M | -1.75%60.76M | 184.04%70.49M | 58.32%46.62M | 83.16%51.87M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -724.43%-764.91M | -887.35%-309.95M | -518.35%-179.95M | -444.98%-211.24M | 0.81%-63.76M | 52.27%-92.78M | 178.24%39.37M | 78.49%-29.1M | -1,484.06%-38.76M | -920.03%-64.28M |
Net PPE purchase and sale | -706.22%-674.96M | -894.05%-301.62M | -298.07%-120.02M | -365.26%-194.83M | -17.73%-58.48M | 62.59%-83.72M | 173.95%37.99M | 77.85%-30.15M | -45.42%-41.88M | -561.92%-49.68M |
Net other investing changes | -892.73%-89.95M | -703.26%-8.33M | -5,812.96%-59.93M | -627.01%-16.41M | 63.85%-5.28M | -130.81%-9.06M | 31.77%1.38M | 29.83%1.05M | -88.18%3.11M | -1,314.05%-14.61M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -724.43%-764.91M | -887.35%-309.95M | -518.35%-179.95M | -444.98%-211.24M | 0.81%-63.76M | 52.27%-92.78M | 178.24%39.37M | 78.49%-29.1M | -1,484.06%-38.76M | -920.03%-64.28M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 867.94%444.98M | 2,094.57%269.36M | 223.56%50.38M | 1,224.63%195.09M | -477.27%-69.85M | -233.74%-57.94M | 415.04%12.27M | -134.54%-40.77M | 52.00%-17.35M | 65.11%-12.1M |
Net issuance payments of debt | 1,271.40%465.67M | 1,146.76%277.99M | 205.32%41.78M | 2,065.82%214.77M | -501.05%-68.87M | -172.07%-39.75M | 868.86%22.3M | -133.41%-39.67M | 61.57%-10.93M | 64.48%-11.46M |
Net common stock issuance | -42.31%-8.24M | -480.35%-1M | ---1.12M | ---- | ---- | 34.91%-5.79M | -8.81%-173K | --0 | ---- | ---- |
Net preferred stock issuance | --13.05M | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Cash dividends paid | -337.52%-14.18M | -132.96%-1.87M | -309.65%-3.36M | -902.37%-8.04M | -12.33%-920K | 0.83%-3.24M | 4.30%-801K | -1.11%-819K | 0.00%-802K | 0.00%-819K |
Proceeds from stock option exercised by employees | -4.38%262K | 150.00%1K | -14.14%85K | ---2K | 0.56%178K | -18.21%274K | ---2K | -41.76%99K | --0 | 7.27%177K |
Net other financing activities | -22.79%-11.58M | 36.32%-5.76M | ---62K | ---5.52M | ---240K | ---9.43M | ---9.05M | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 867.94%444.98M | 2,094.57%269.36M | 223.56%50.38M | 1,224.63%195.09M | -477.27%-69.85M | -233.74%-57.94M | 415.04%12.27M | -134.54%-40.77M | 52.00%-17.35M | 65.11%-12.1M |
Net cash flow | ||||||||||
Beginning cash position | 88.76%168.03M | 88.96%105.12M | 168.87%147.91M | 46.10%94.24M | 88.76%168.03M | -6.93%89.02M | -31.65%55.63M | -25.50%55.01M | -22.26%64.51M | -6.93%89.02M |
Current changes in cash | -144.96%-35.53M | -75.64%27.38M | -7,001.45%-42.79M | 665.37%53.67M | -201.04%-73.79M | 1,292.65%79.01M | 1,373.29%112.4M | -91.78%620K | -3.86%-9.49M | -93.59%-24.51M |
End cash Position | -21.14%132.5M | -21.14%132.5M | 88.96%105.12M | 168.87%147.91M | 46.10%94.24M | 88.76%168.03M | 88.76%168.03M | -31.65%55.63M | -25.50%55.01M | -22.26%64.51M |
Free cash flow | -1,021.48%-561.7M | -841.58%-286.95M | -309.28%-81.12M | -1,612.23%-190.26M | 37.49%-3.37M | 141.02%60.96M | 815.51%38.7M | 133.13%38.76M | 62.65%-11.11M | -251.35%-5.39M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |